Aryx Therapeutics files for $86M IPO
Aryx Therapeutics is headed to the public market for a bucketload of cash. If all goes according to plan, it will raise $86.3 million through the sale of an undisclosed number of shares. Aryx has been developing new therapies out of established drugs, saying that it knows of a safer pathway that metabolizes drugs differently--a process expected to reduce the potential for adverse side effects. Aryx has a pact with P&G to develop cisapride for gastrointestinal disorders. That therapy just wrapped Phase II. Aryx lost $12.2 million in the six months ended June 30.
- check out the AP report for more info
Be the first to comment
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets


